Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbmV4NWgtNHIxcFNOYk8tdEdrZVQ2cmdKQUJsWG12bUszbXVLN3NJZWo1VnowM0NocTVPb3RtQ2dSWE5JeXJiRnF4RkR4LVlGcEtrZHRTWUxnS3UyajM3QUlUbDVhZ0pqZWdCSE5QRS1QTE9BekIyTlF2OFZqZFF0SHZCaHZVTHZ3amRfd3VUdGZUSUlsQm9jZDg5M3FHaDBDdGFkc1hFM0t3U1N6SkxvamppdUMyVmFicHA0VDZDSQ?oc=5" target="_blank">Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say</a> <font color="#6f6f6f">Reuters</font>
Inhibrx Biosciences is exploring a joint spin-off of its experimental cancer drug, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The potential valuation of the drug could exceed $8 billion if clinical trials confirm its efficacy.
Merck & Co, Germany's Merck KGaA, and Japan's Ono Pharmaceutical are reportedly interested in Inhibrx's experimental cancer treatment, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The drug could be valued at over $8 billion if clinical trials are successful.
Similar Stories
Related coverage based on topic and tags
Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMBASF considers raising offer for Evonik, sources say - Reuters
BASF considers raising offer for Evonik, sources say Reuters
October 9, 2026 at 02:02 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMMcKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal - Reuters
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal Reuters
October 6, 2026 at 04:30 PM